A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers - PubMed (original) (raw)
. 2010 Mar 15;70(6):2158-64.
doi: 10.1158/0008-5472.CAN-09-3458. Epub 2010 Mar 9.
Gayatry Mohapatra, Miguel N Rivera, Daniel Winokur, Patricia Greninger, Mai Nitta, Peter M Sadow, Gaya Sooriyakumar, Brian W Brannigan, Matthew J Ulman, Rushika M Perera, Rui Wang, Angela Tam, Xiao-Jun Ma, Mark Erlander, Dennis C Sgroi, James W Rocco, Mark W Lingen, Ezra E W Cohen, David N Louis, Jeffrey Settleman, Daniel A Haber
Affiliations
- PMID: 20215515
- PMCID: PMC2881662
- DOI: 10.1158/0008-5472.CAN-09-3458
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers
S Michael Rothenberg et al. Cancer Res. 2010.
Abstract
In a genome-wide screen of 684 cancer cell lines, we identified homozygous intragenic microdeletions involving genes encoding components of the apical-basal cell polarity complexes. Among these, PARD3 is disrupted in cell lines and primary tumors from squamous carcinomas and glioblastomas. Reconstituting PARD3 expression in both cell types restores tight junctions and retards contact-dependent proliferation. Searching specifically for small intragenic microdeletions using high-resolution genomic arrays may be complementary to other genomic deletion screens and resequencing efforts in identifying new tumor suppressor genes.
Figures
Fig. 1
Deletions in polarity complex genes in human tumor samples. (a) Human tumor cell lines with homozygous deletions in polarity complex genes. (b) Mapping of deleted regions to the domain structure of PARD3. *samples with aberrant transcripts encoding frameshift mutations. **splice site point mutation leads to aberrant splicing.
Fig. 2
Intragenic PARD3 deletions in human cancer cell lines. (a) Heat map (left) and graphical display (right) demonstrating intragenic, homozygous PARD3 deletions in esophagus and head and neck squamous carcinoma cell lines. Deviations to the left of the red line denoting normal copy number (to ~ log[2] −2) represent deleted probes. (b) PCR of genomic DNA confirms the location of the missing exons. (c) RT-PCR of SCCHN cell line DOK (genomic deletion exons 4–5) reveals a truncated transcript from fusion of exons 3 and 6 (left), leading to a frameshift, stop codon (middle) and loss of PARD3 expression (right).
Fig. 3
PARD3 mutations in human primary tumors. (a) FISH identifies a heterozygous intragenic deletion within PARD3 in a primary SCCHN (left). Only one of two red signals for BAC RP11-198D23 is present in tumor nuclei (T, upper right panel, 44% nuclei) compared to matched normal tissue bordering the tumor (N, upper left--two signals in 94.6% nuclei). FISH with PARD3 BACs surrounding the deleted region demonstrates two signals for each probe (lower panels). RT-PCR (upper right) detects a truncated transcript, the result of out-of-frame fusion of exons 3 and 9 with loss of the intervening exons (lower right). (b) Homozygous deletion of exons 7–8 and 14–16 in a primary glioblastoma. A and B represent two different primer sets for exons 7 and 15. (c) A somatic G-A mutation present in GBM tumor DNA (asterix) but not DNA from matched normal blood (left sequence traces) leads to a truncated transcript (agarose gel image), the likely result of aberrant splicing that joins sequences within exons 9 and 10, with loss of the intervening sequence (right traces).
Fig. 4
Effect of gain-of-function of PARD3. (a) Restoration of PARD3 expression in squamous carcinoma and glioblastoma cell lines with endogenous deletions. (b,c) Re-expression of PARD3 relocalizes ZO-1 to cell-cell contacts. Arrows indicate location of PARD3 or ZO-1. Asterixes indicate discontinuous ZO-1 staining at some cell borders in control cells. (d) Restoring PARD3 expression in KYSE-30 SCCE cells retards cell growth. The arrow indicates when the cells first appeared to make cell-cell contacts. Cells were plated at 1e5 cells/well in 6-well plates in triplicate. Every 3–4 days, cells were trypsinized and counted. Mean and standard error of the mean (n=3) for one of two representative experiments is shown. *P=0.004. **P=0.005. ***P=0.018 (alpha = 0.05, two-sided, unpaired student’s t-test).
Similar articles
- Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma.
Zen K, Yasui K, Gen Y, Dohi O, Wakabayashi N, Mitsufuji S, Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, Okanoue T, Yoshikawa T. Zen K, et al. Oncogene. 2009 Aug 13;28(32):2910-8. doi: 10.1038/onc.2009.148. Epub 2009 Jun 8. Oncogene. 2009. PMID: 19503097 - Aberrant expression of the tight junction molecules claudin-1 and zonula occludens-1 mediates cell growth and invasion in oral squamous cell carcinoma.
Babkair H, Yamazaki M, Uddin MS, Maruyama S, Abé T, Essa A, Sumita Y, Ahsan MS, Swelam W, Cheng J, Saku T. Babkair H, et al. Hum Pathol. 2016 Nov;57:51-60. doi: 10.1016/j.humpath.2016.07.001. Epub 2016 Jul 17. Hum Pathol. 2016. PMID: 27436828 - Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma.
Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, Plass C. Bennett KL, et al. Cancer Res. 2008 Jun 15;68(12):4494-9. doi: 10.1158/0008-5472.CAN-07-6509. Cancer Res. 2008. PMID: 18559491 - Prognostic biomarkers in head and neck cancer.
Grandis JR. Grandis JR. Clin Cancer Res. 2006 Sep 1;12(17):5005-6. doi: 10.1158/1078-0432.CCR-06-1356. Clin Cancer Res. 2006. PMID: 16951212 Review. No abstract available. - The polarity protein PARD3 and cancer.
Atashrazm F, Ellis S. Atashrazm F, et al. Oncogene. 2021 Jun;40(25):4245-4262. doi: 10.1038/s41388-021-01813-6. Epub 2021 Jun 7. Oncogene. 2021. PMID: 34099863 Review.
Cited by
- Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway.
Wei X, Liu Q, Liu L, Wang D, Liu J, Zhu Q, Xu Z, Chen Q, Xu W. Wei X, et al. Int J Mol Sci. 2024 Jul 21;25(14):7973. doi: 10.3390/ijms25147973. Int J Mol Sci. 2024. PMID: 39063214 Free PMC article. - Therapy-induced modulation of tumor vasculature and oxygenation in a murine glioblastoma model quantified by deep learning-based feature extraction.
Bauer N, Beckmann D, Reinhardt D, Frost N, Bobe S, Erapaneedi R, Risse B, Kiefer F. Bauer N, et al. Sci Rep. 2024 Jan 23;14(1):2034. doi: 10.1038/s41598-024-52268-0. Sci Rep. 2024. PMID: 38263339 Free PMC article. - Dual Function of Par3 in Tumorigenesis.
Lv T, Xu J, Yuan H, Wang J, Jiang X. Lv T, et al. Front Oncol. 2022 Jul 8;12:915957. doi: 10.3389/fonc.2022.915957. eCollection 2022. Front Oncol. 2022. PMID: 35875120 Free PMC article. Review. - The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma.
Dadras MS, Caja L, Mezheyeuski A, Liu S, Gélabert C, Gomez-Puerto MC, Gallini R, Rubin CJ, Ten Dijke P, Heldin CH, Moustakas A. Dadras MS, et al. Cell Death Dis. 2021 Oct 12;12(10):932. doi: 10.1038/s41419-021-04220-7. Cell Death Dis. 2021. PMID: 34642295 Free PMC article. - Cell polarity and cell adhesion associated gene expression differences between invasive micropapillary and no special type breast carcinomas and their prognostic significance.
Kramer Z, Kenessey I, Gángó A, Lendvai G, Kulka J, Tőkés AM. Kramer Z, et al. Sci Rep. 2021 Sep 16;11(1):18484. doi: 10.1038/s41598-021-97347-8. Sci Rep. 2021. PMID: 34531452 Free PMC article.
References
- Lisitsyn NA, Segre JA, Kusumi K, et al. Direct isolation of polymorphic markers linked to a trait by genetically directed representational difference analysis. Nature genetics. 1994;6:57–63. - PubMed
- Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature genetics. 1998;20:207–11. - PubMed
- Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature genetics. 1999;23:41–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 DK080175-03/DK/NIDDK NIH HHS/United States
- R01 CA129933/CA/NCI NIH HHS/United States
- R01 CA207186/CA/NCI NIH HHS/United States
- R37 CA058596/CA/NCI NIH HHS/United States
- K08 DK080175/DK/NIDDK NIH HHS/United States
- R01 CA057683-16S1/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R01 CA57683/CA/NCI NIH HHS/United States
- R01 CA057683/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials